Zions Bancorporation National Association UT Takes $11.50 Million Position in Sanofi (NASDAQ:SNY)

Key Points

• Zions Bancorporation National Association UT has invested approximately $11.50 million in Sanofi, purchasing 207,346 shares, making it the firm's 19th largest position.
• Sanofi's recent earnings report indicated a missed EPS estimate of $0.90 versus the expected $0.96, while the company's revenue surpassed expectations at $11.34 billion.
• Several analysts have upgraded their ratings on Sanofi, with JPMorgan Chase & Co. raising it to "overweight" and setting a consensus price target of $62.00.

Zions Bancorporation National Association UT bought a new stake in Sanofi (NASDAQ:SNY - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 207,346 shares of the company's stock, valued at approximately $11,499,000. Sanofi comprises 0.7% of Zions Bancorporation National Association UT's portfolio, making the stock its 19th largest position.

Several other institutional investors have also added to or reduced their stakes in the stock. Accent Capital Management LLC bought a new position in shares of Sanofi during the 1st quarter worth approximately $29,000. Eastern Bank boosted its holdings in shares of Sanofi by 121.0% during the 1st quarter. Eastern Bank now owns 548 shares of the company's stock worth $30,000 after buying an additional 300 shares in the last quarter. Golden State Wealth Management LLC boosted its holdings in shares of Sanofi by 619.3% during the 1st quarter. Golden State Wealth Management LLC now owns 633 shares of the company's stock worth $35,000 after buying an additional 545 shares in the last quarter. Bessemer Group Inc. boosted its holdings in shares of Sanofi by 59.8% during the 4th quarter. Bessemer Group Inc. now owns 647 shares of the company's stock worth $32,000 after buying an additional 242 shares in the last quarter. Finally, Brentview Investment Management LLC bought a new position in shares of Sanofi during the 1st quarter worth approximately $42,000. 14.04% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on SNY shares. Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of Sanofi in a report on Tuesday. JPMorgan Chase & Co. upgraded Sanofi from a "neutral" rating to an "overweight" rating in a report on Friday. Barclays reiterated an "overweight" rating on shares of Sanofi in a report on Wednesday, July 2nd. Guggenheim reiterated a "buy" rating on shares of Sanofi in a report on Tuesday, June 3rd. Finally, Morgan Stanley set a $56.00 target price on Sanofi in a report on Monday, June 2nd. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Sanofi presently has a consensus rating of "Buy" and an average price target of $62.00.

Sanofi Stock Down 0.6%

NASDAQ SNY traded down $0.28 on Friday, reaching $47.16. The company had a trading volume of 2,968,334 shares, compared to its average volume of 2,427,230. The stock has a market capitalization of $115.79 billion, a P/E ratio of 11.34, a P/E/G ratio of 1.13 and a beta of 0.48. The company's fifty day moving average is $48.67 and its 200 day moving average is $51.97. Sanofi has a 52-week low of $44.73 and a 52-week high of $60.12. The company has a quick ratio of 0.94, a current ratio of 1.27 and a debt-to-equity ratio of 0.19.

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The company reported $0.90 EPS for the quarter, missing analysts' consensus estimates of $0.96 by ($0.06). The company had revenue of $11.34 billion during the quarter, compared to analysts' expectations of $9.91 billion. Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The company's quarterly revenue was down 7.0% compared to the same quarter last year. During the same period in the previous year, the company posted $1.73 earnings per share. Sell-side analysts anticipate that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.